NextCure, Inc.NXTCNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank50
3Y CAGR-6.3%
5Y CAGR-0.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-6.3%/yr
vs +28.6%/yr prior
5Y CAGR
-0.9%/yr
Recent deceleration
Acceleration
-35.0pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$44.56M+7.4%
2024$41.49M-13.4%
2023$47.93M-11.6%
2022$54.20M+8.0%
2021$50.19M+7.8%
2020$46.55M+36.1%
2019$34.22M+72.9%
2018$19.79M+52.7%
2017$12.95M-